E Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.17M | Sell |
3,594
-9,114
| -72% | -$2.97M | 0.06% | 147 |
|
|
2025
Q1 | $3.43M | Buy |
12,708
+413
| +3% | +$112K | 0.16% | 87 |
|
|
2024
Q4 | $2.89M | Sell |
12,295
-342
| -3% | -$80.5K | 0.15% | 86 |
|
|
2024
Q3 | $3.48M | Buy |
12,637
+7,711
| +157% | +$2.12M | 0.18% | 63 |
|
|
2024
Q2 | $1.2M | Buy |
4,926
+2,112
| +75% | +$513K | 0.07% | 112 |
|
|
2024
Q1 | $421K | Sell |
2,814
-526
| -16% | -$78.6K | 0.03% | 198 |
|
|
2023
Q4 | $639K | Buy |
3,340
+1,069
| +47% | +$205K | 0.04% | 119 |
|
|
2023
Q3 | $402K | Sell |
2,271
-70
| -3% | -$12.4K | 0.03% | 168 |
|
|
2023
Q2 | $445K | Buy |
2,341
+226
| +11% | +$43K | 0.04% | 134 |
|
|
2023
Q1 | $424K | Buy |
2,115
+287
| +16% | +$57.5K | 0.03% | 147 |
|
|
2022
Q4 | $434K | Sell |
1,828
-306
| -14% | -$72.7K | 0.04% | 162 |
|
|
2022
Q3 | $427K | Sell |
2,134
-1,181
| -36% | -$236K | 0.04% | 164 |
|
|
2022
Q2 | $483K | Buy |
3,315
+1,583
| +91% | +$231K | 0.04% | 145 |
|
|
2022
Q1 | $283K | Buy |
+1,732
| New | +$283K | 0.01% | 218 |
|